Carer Perspective: Pancreatic Cancer
Cherie Dear is a carer for her husband Paul, who was diagnosed with metastatic pancreatic cancer in September of 2020 and began...
PANCREATIC
Pancreatic Summits
Diagnosis and treatment of pancreatic cancer has a significant physical and emotional impact on patients and their loved ones.
The Victorian Tumour Summits are clinician-led forums seeking to identify unwarranted variations in tumour based clinical practice and cancer outcomes that could be addressed through state-wide action.
Seventy stakeholders from across Victoria gathered on November 24, 2017 to discuss variations in care and identify opportunities for improvement.
Pancreatic Cancer 2017 Clinical Working Party
-
Dr Rob Blum
-
Prof Christopher Christophi
-
Mr Dan Croagh
-
Mr David Deutscher
-
Mr Adrian Fox
-
A/Prof Peter Gibbs
-
Mr George Kalogeropoulos
-
Dr Richard Khor
-
A/Prof Brian Le
-
Dr Belinda Lee
-
Mr Mehrdad Nikfarjam
-
Mr Charles Pilgrim (Chair)
-
Dr Babak Tamjid
-
A/Prof Niall Tebbutt
-
A/Prof Ben Thomson
-
A/Prof Valery Usatoff
-
Prof John Zalcberg
Pancreatic Cancer 2017 Summit Material
Pancreatic 2017 Summit Introduction Presentation
Prof. Robert Thomas
Pancreatic 2017 Summit Policy Context Presentation
Presented by Kathryn Whitfield
Pancreatic Cancer 2017 Summit Data Presentation
Presented by Dr Charles Pilgrim
Data Variations
Pancreatic 2017 Summit Clinical Working Party Chair Dr Charles Pilgrim presented on the variations in statewide data:
-
One-year relative survival increased from 27% to 34% between 2011-15.
-
Post-operative mortality is low by international standards: 2.1% (30 days); 2.7% (90 days); 19.7% (1-year).
-
A decrease in the number of Victorian hospitals conducting low volumes of pancreatic resections (1-3 per year) from 10 to 4 between the 2014/15 and 2016/17 financial years.
-
Only 5% of patients who had curative surgery for non-metastatic pancreatic ductal adenocarcinoma had neoadjuvant therapy.
-
23% of patients who had curative surgery for non-metastatic pancreatic ductal adenocarcinoma did not have adjuvant therapy.